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Death of enteric neurons contributes to motility dysfunction
in gastrointestinal disorders. Our work provides the ﬁrst
evidence of glial activation as a driver of enteric
neurodegeneration.
BACKGROUND & AIMS: The concept of enteric glia as
regulators of intestinal homeostasis is slowly gaining
acceptance as a central concept in neurogastroenterology.
Yet how glia contribute to intestinal disease is still poorly
understood. Purines generated during inﬂammation drive
enteric neuron death by activating neuronal P2X7 purine
receptors (P2X7R); triggering adenosine triphosphate
(ATP) release via neuronal pannexin-1 channels that subse-
quently recruits intracellular calcium ([Ca2þ]i) in surround-
ing enteric glia. We tested the hypothesis that the
activation of enteric glia contributes to neuron death during
inﬂammation.
METHODS: We studied neuroinﬂammation in vivo using the
2,4-dinitrobenzene sulfonic acid model of colitis and in situ
using whole-mount preparations of human and mouse in-
testine. Transgenic mice with a targeted deletion of glial
connexin-43 (Cx43) [GFAP::CreERT2þ//Cx43f/f] were used
to speciﬁcally disrupt glial signaling pathways. Mice deﬁcient
in inducible nitric oxide (NO) synthase (iNOS/) were used
to study NO production. Protein expression and oxidative
stress were measured using immunohistochemistry and in
situ Ca2þ and NO imaging were used to monitor glial [Ca2þ]i
and [NO]i.
RESULTS: Purinergic activation of enteric glia drove [Ca2þ]i
responses and enteric neuron death through a Cx43-dependent
mechanism. Neurotoxic Cx43 activity, driven by NO production
from glial iNOS, was required for neuron death. Glial Cx43
opening liberated ATP and Cx43-dependent ATP release was
potentiated by NO.
CONCLUSIONS: Our results show that the activation of glial
cells in the context of neuroinﬂammation kills enteric neu-
rons. Mediators of inﬂammation that include ATP and NO
activate neurotoxic pathways that converge on glial Cx43
hemichannels. The glial response to inﬂammatory media-
tors might contribute to the development of motility disorders.
(Cell Mol Gastroenterol Hepatol 2016;2:77–91; http://dx.doi.org/
10.1016/j.jcmgh.2015.08.007)Keywords: Enteric Nervous System; Hemichannels; Oxidative
Stress; Purines.
eﬂex behaviors of the intestine, such as peristalsis,Rare orchestrated by the enteric nervous system
(ENS); a complex network of neurons and glia embedded in
the gut wall. The basic neural circuitry of the ENS is now
well deﬁned and it is generally accepted that the breakdown
of ENS control is a major contributing factor in the devel-
opment of functional bowel disorders.1 However, it is only
recently that we are beginning to appreciate the potential
roles of enteric glial cells in the physiology and patho-
physiology of the ENS.2 Despite intense interest in enteric
glia as regulators of enteric neurons, the precise functions of
enteric glia remain poorly deﬁned.
Enteric glia are a unique population of peripheral astro-
glial cells that surround enteric neurons and are thought to
sustain neural signaling and survival. In support, enteric glia
secrete neuroprotective factors3 and the selective ablation of
glial signaling alters the neural control of motility.4 Likewise,
in vivo models of glial ablation cause enteric neuron death.5,6
Thus, the loss of glial supportive functions is postulated as a
potential mechanism contributing to enteric neuropathy.2
Table 1.Primary Antibodies Used
Antibody Source Dilution
Catalog
No.
Rabbit anti-iNOS Abcam, Cambridge,
MA
1:200 ab15323
Biotinylated mouse
anti-human HuC/D
Molecular Probes,
Grand Island, NY
1:200 A-21272
Chicken anti-GFAP Abcam 1:1000 ab4674
Rabbit anti-
nitrotyrosine
Millipore,
Billerica, MA
1:100 06-284
Rabbit
anti-P2Y1R
Alomone Labs,
Jerusalem, Israel
1:200 APR-021
GFAP, glial ﬁbrillary acidic protein; iNOS, inducible nitric
oxide synthase; P2Y1R, P2Y1 receptor.
Table 2.Secondary Antibodies Used
Antibody Source Dilution
Catalog
No.
Alexa Fluor 488
Goat anti-
rabbit
Invitrogen,
Carlsbad, CA
1:200 A-11034
Alexa Fluor 488
Goat anti-
chicken
Invitrogen 1:200 A-11039
Alexa Fluor 568
Goat anti-
chicken
Invitrogen 1:200 A-11041
Alexa Fluor 594-
conjugated
streptavidin
Jackson Immuno
Research,
West Grove, PA
1:200 016-580-084
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rather than glial cell loss, is responsible for driving neuro-
degeneration during neuroinﬂammation in the brain.7 Indeed,
the conversion of astroglia to reactive astrocytes can promote
the secretion of factors that promote neuron death.8
We recently discovered that enteric glia are activated by
purines released from enteric neurons before neuronal
death during colitis.9 Speciﬁcally, the activation of neuronal
P2X7 purine receptors (P2X7Rs) triggers the release of
adenosine triphosphate (ATP) from neurons through
pannexin-1 (panx1) channels as a signal to enteric glia. In
the brain, neuronal ATP release through panx1 is consid-
ered a danger signal that glial cells interpret as a “search
and destroy” message, causing glia to execute otherwise
healthy neurons. Given that stimulation of P2Y1Rs is a
potent stimulus for reactive astrogliosis in the central ner-
vous system,10 we hypothesized that the activation of glial
purine receptors contributes to neuropathy in the ENS.
We tested our hypothesis using a combination of in vivo
models of colitis with inducible and conditional transgenic
mice and ex vivo intestinal preparations to address speciﬁc
mechanisms. Our data show that glial activation is sufﬁcient
to cause enteric neuron death via a mechanism that depends
on the activation of connexin-43 (Cx43) hemichannels and
subsequent ATP release. Surprisingly, our data show that
glial-driven neuron death requires the gating of glial Cx43
hemichannels by nitric oxide (NO). In all, our results suggest
that the activation of enteric glial cells is a central mecha-
nism in the development of enteric neuropathy.
Materials and Methods
Animals
All work involving animals was approved by the Institu-
tional Animal Care and Use Committee (IACUC) of Michigan
State University. Male mice (8–10 weeks of age) were main-
tained on a 12-hour light/dark cycle with access to food and
water ad libitum. C57Bl/6micewere purchased from Charles
River Laboratories (Hollister, CA) and the inducible nitric
oxide synthase (iNOS) null mice (B6.129S2-Nos2tm1MrlN12;
Taconic Labs; RRID: MGI_4837857; hereafter referred to as
iNOS/) from Taconic Farms (Germantown, NY).11 Trans-
genic mice with an inducible and conditional deletion of Cx43
in glial ﬁbrillary acidic protein (GFAP)-expressing glia
(GFAP::CreERT2þ//Cx43f/f; hereafter referred to as Cx43i-
cKO) and their Cre-negative littermate controls
(GFAP::CreERT2þ/þ/Cx43f/f) were generated in-house as pre-
viously described4 by crossing GFAP::CreERT2þ/ mice
[(GFAP-cre/ERT2)505Fmv/J; Jackson Laboratory (Bar Har-
bor, ME); RRID: IMSR_JAX:012849] with Cx43f/f mice
(B6.129S7-Gja1tm1Dlg/J; Jackson Laboratory; RRID:
IMSR_JAX:008039). Cre recombinase activity was induced by
feeding animals tamoxifen citrate in chow (400 mg/kg) for 2
weeks. Animals were returned to normal chow for 1 week to
clear tamoxifen before beginning experiments.
Human Tissue
Work involving human tissue was approved by the
institutional review board of Michigan State University(IRB 13-945M). Samples of live, full-thickness human
jejunum were collected from a 57-year-old woman with
hypertension and type 2 diabetes who underwent elective
laparoscopic bariatric surgery for weight loss. The samples
were placed in chilled Dulbecco’s modiﬁed Eagle medium
(DMEM)/F-12 medium during transfer to the laboratory.
Live longitudinal muscle myenteric plexus (LMMP) whole-
mount preparations were prepared by microdissection for
calcium (Ca2þ) imaging.Whole-Mount Immunohistochemistry
Whole-mount preparations of mouse colonic LMMP were
prepared by microdissection from tissue preserved in
Zamboni’s ﬁxative. Processing of LMMPs via immunohisto-
chemistry was conducted as described elsewhere4 with the
primary and secondary antibodies listed in Tables 1 and 2,
respectively. Brieﬂy, LMMP preparations underwent three
10-minute washes in 0.1% Triton X-100 in phosphate-
buffered saline (PBS) followed by a 45-minute incubation
in blocking solution containing 4% normal goat serum, 0.4%
Triton X-100 and 1% bovine serum albumin. Preparations
were incubated in primary antibodies (listed in Table 1) for
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for 2 hours at room temperature before mounting.
Antibody speciﬁcity was conﬁrmed by preadsorption
with the corresponding control peptides or in knockout
mice as described elsewhere.9 Fluorescent labeling was
visualized using the 40 objective (0.75 numerical aper-
ture; Plan Fluor, Nikon, Melville, NY) of an upright epi-
ﬂuorescence microscope (Nikon Eclipse Ni) with a Retiga
2000R camera (QImaging, Surrey, BC, Canada) controlled by
QCapture Pro 7.0 (QImaging) software or by confocal im-
aging through the Plan-Apochromat 60 oil immersion
objective (1.42 numerical aperture) of an inverted Olympus
Fluoview FV1000 microscope (Olympus, Center Valley, PA).
Quantiﬁcation of Neuronal Thiol Oxidation
We quantiﬁed neuronal thiol oxidation as a measure of
oxidative stress as described elsewhere.12 Reduced (-SH)
and oxidized (-SS) thiols were labeled in live LMMP prep-
arations with 1 mM Alexa Fluor 680 C2 maleimide and 1 mM
Alexa Fluor 546 C5 maleimide, respectively. Alexa Fluor 680
C2 maleimide was dissolved in 4% paraformaldehyde,
0.02% Triton X-100 and 1 mM N-ethylmaleimide in PBS and
Alexa Fluor 546 C5 maleimide was dissolved in 1 mM N-
ethylmaleimide in PBS. Oxidized thiols were converted to
reduced thiols for labeling by washing tissue in 5 mM tris(2-
carboxyethyl)phosphine hydrochloride in PBS for 20 mi-
nutes. Images were obtained by epiﬂuorescence microscopy
as described above and the ratio of 546-maleimide/680-
maleimide (SS/SH) calculated with ImageJ software
(http://imagej.nih.gov/ij/).
Dihydroethidium Staining
Superoxide levels were measured by quantifying ﬂuo-
rescence of the superoxide marker dihydroethidium
(DHE)13 in live ganglia in LMMP whole mount preparations
after a 1 hour of incubation with 2 mM DHE (Life Technol-
ogies, Carlsbad, CA) dissolved in DMEM at 37C.
In Situ Model of Neuroinﬂammation
Enteric neuron death was driven as previously
described9 by incubating live LMMP preparations with the
P2X7R agonist 20(30)-O-(4-benzoylbenzoyl)adenosine 50-
triphosphate triethylammonium salt (BzATP) (300 mM) for
2 hours in 95% air: 5% CO2 at 37C. LMMP preparations
were then rinsed with fresh buffer, incubated for an addi-
tional 2 hours in Kreb’s buffer only, and ﬁxed in Zamboni’s
ﬁxative overnight.
Calcium and Nitric Oxide Imaging
Live LMMP whole mount preparations were loaded with
4 mM Fluo-4-AM or DAF-FM [4-amino-5-methylamino-20,70-
diﬂuoroﬂuorescein] (Life Technologies) for 45 minutes at
37C as described elsewhere4 to measure intracellular Ca2þ
and NO, respectively. The loaded tissue was continuously
perfused with prewarmed buffer (34C, 3 mL/min) and
drugs were bath applied. Images were acquired every 1–5
seconds with a Neo sCMOS digital camera (Andor, SouthWindsor, CT) through the 40 water-immersion objective
(LUMPlan N, 0.8 n.a.) of an upright Olympus BX51W1 ﬁxed-
stage microscope controlled by Andor IQ3 software.Determination of Cell Viability
Cell viability was determined using calcein-AM; a hy-
drophobic compound that is converted to hydrophilic,
ﬂuorescent calcein in live, membrane-intact cells.14 The
calcein-AM cell viability assay is a simple, rapid, and ac-
curate method to measure cytotoxicity that is not
dependent upon the mode of cell death and is a true end-
point assay for cell viability. Nonﬂuorescent, hydrophobic
calcein-AM easily permeates live cells where it is acted
upon by esterases, producing the strongly ﬂuorescent
hydrophilic compound calcien, which is retained in the
cell cytoplasm. A loss of membrane integrity in dying
cells permits the dye to escape from the cell and a loss of
cellular ﬂuorescence is indicative of neuron death. Live
LMMPs were loaded with 4 mM calcien-AM for 30 mi-
nutes at 37C after in situ induction of neuro-
inﬂammation with BzATP (300 mM) or adenosine 50-
diphosphate monopotassium salt dihydrate (ADP, 100
mM) or incubation with buffer in control samples. Images
of 10 ganglia per whole mount were acquired as
described for Ca2þ imaging and the neuronal density
calculated based on the number of live (ﬂuorescent) cells
per ganglionic area.Detection of ATP Release
The release of ATP was measured using an in-house-
fabricated, selective ATP sensor.15,16 LMMPs were continu-
ously perfused with buffer (34C, 6 mL/min) and ATP
release was stimulated by bath application of either BzATP
(300 mM) or adenosine 50-[b-thio]diphosphate trilithium
salt (ADPbS, 100 mM) in the presence or absence of drugs.
The ATP-selective sensor was placed directly on a ganglion
and a superfusion pipette was located within 100 mm of the
sensor. Traces were analyzed by measuring the area under
the curve and converting this to the concentration of ATP
using preobtained calibration curves.15Induction of Colitis
Colitis was induced in mice via an enema of dinitro-
benzene sulfonic acid (DNBS, 5.5 mg/mouse in 0.1 mL
ethanol/saline administered via a gavage needle inserted 3
cm into the colon) as described elsewhere.9 Animal weight
was recorded daily and the tissue was harvested 6 and 48
hours after DNBS treatment. Upon tissue collection,
macroscopic damage was assessed to quantify acute
inﬂammation.17 Macroscopic damage assessment scored for
the presence of colonic ulcers, hemorrhaging, fecal blood,
diarrhea, increased colon wall thickness and adhesion of the
colon to the peritoneal cavity and/or other organs. Inﬂam-
mation was classiﬁed as mild if damage scores were <1,
moderate if scores were >1 but <5 and severe if the scores
were >5.
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BzATP, ADP, ADPbS, N-ethylmaleimide, and tris(2-
carboxyethyl)phosphine hydrochloride were purchased
from Sigma-Aldrich (St. Louis, MO) and MRS2365 [triso-
dium;[[(1R,2R,3S,5S)-4-(6-amino-2-methylsulfanylpurin-9-yl)-
2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methoxy-oxidophos-
phoryl] phosphate] and A-740003; [N-(1-{[(cyanoimino)(5-
quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-
(3,4-dimethoxyphenyl)acetamide] from Tocris Bioscience
(Bristol, United Kingdom). We purchased 1400W [N-([3-
(aminomethyl)phenyl]methyl)ethanimidamide dihydro-
chloride], L-NAME (Nu-nitro-L-arginine methyl ester) and
propylamine propylamine NONOate (PAPA NONOate) from
Cayman Chemical (Ann Arbor, MI). The Cx43 hemichannel
mimetic peptide 43Gap26 and panx1 mimetic peptide
10panx were purchased from Anaspec (Fremont, CA).
Solutions
Live tissue was maintained in DMEM/F-12 nutrient
mixture (Life Technologies) containing 3 mM nicardipine
and 1 mM scopolamine during microdissection and in-
cubations. LMMPs were perfused with modiﬁed Krebs
buffer containing (in mM): 121 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2
MgCl2, 1.2 NaH2PO4, 10 HEPES, 21.2 NaHCO3, 1 pyruvic acid,
and 8 glucose (pH adjusted to 7.4 with NaOH) with 3 mM
nicardipine and 1 mM scopolamine.
Data and Statistical Analysis
Average ﬂuorescence intensity was quantiﬁed by
measuring average ﬂuorescence using the measure function
in ImageJ software, version 1.49 (National Institutes of
Health). Neuron packing density was determined by
counting the number of HuC/D-immunoreactive neurons
per ganglionic area in 10 ganglia per LMMP preparation
using the cell counter plug-in tool in ImageJ. All results are
presented as mean ± standard error of the mean (SEM) and
statistically signiﬁcant differences were determined using
an analysis of variance (ANOVA) or t test, as appropriate
with P < .05 considered statistically signiﬁcant (GraphPad
Prism; GraphPad Software, San Diego, CA). For Ca2þ and NO
imaging, traces represent the average change in ﬂuores-
cence (DF/F) over time for all glial cells within a single
ganglion. All authors had access to the study data and
reviewed and approved the ﬁnal manuscript.
Results
Purinergic Activation of Enteric Glial Cells
Drives Glial Calcium Responses and Enteric
Neuron Death
Enteric neuron death during intestinal inﬂammation re-
quires the activation of neuronal P2X7Rs and neuronal ATP
release through panx1 channels.9 Neuronal ATP released via
panx1 is rapidly hydrolyzed to ADP by eNTPDase2 and ADP
recruits Ca2þ responses in the surrounding enteric glial cells
following stimulation of P2Y1Rs (Figure 1A).9 In agreement
with our previous work in mice, we found that activation of
P2Y1Rs with the agonist ADP stimulates Ca2þ responses inenteric glial cells within the myenteric plexus of the human
jejunum (see Figure 1B). Likewise, activation of neuronal
P2X7Rs with the agonist BzATP in the human myenteric
plexus recruits Ca2þ responses in the surrounding enteric
glial cells (see Figure 1B).
Previous reports suggest that P2Y1Rs are expressed by
enteric neurons in the guinea pig ENS18 and by enteric glia
in the mouse ENS.9,19 Our data support the conclusion that
P2Y1Rs are primarily localized to enteric glia in the mouse
myenteric plexus because P2Y1R agonists including ADP
(100 mM), the nonhydrolyzable ADP analog ADPbS (100
mM) and MRS2365 (1 mM) primarily drive cellular activity in
enteric glial cells and not neurons (see Figure 1C and D, data
not shown for ADP and MRS2365). Likewise, immunohis-
tochemistry with speciﬁc antibodies against an extracellular
loop of the P2Y1R shows that P2Y1Rs are primarily local-
ized to enteric glial cell processes in the myenteric plexus
(see Figure 1E).
Next, we tested how direct activation of glial cells with
P2Y1R agonists affects neuron survival in isolated prepa-
rations of the mouse ENS. Activation of glial P2Y1Rs with
ADP, ADPbS, or MRS2365 decreased the ganglionic density
of HuC/D-immunoreactive neurons by 24% ± 4%, 23% ±
4%, and 19% ± 4%, respectively (see Figure 1F). Impor-
tantly, P2Y1R activation drove enteric neuron death to an
equal extent as activation of neuronal P2X7Rs with BzATP
(300 mM) (23% ± 2%; see Figure 1F).
To conﬁrm that the loss of HuC/D-immunoreactivity
truly reﬂects a loss of neurons and not merely a loss of
HuC/D-immunoreactivity in neurons, we assessed neuronal
viability using the ﬂuorescent dye calcien-AM, which labels
live, membrane-intact cells.14 Treatment with BzATP (300
mM) or ADP (100 mM) decreased neuronal density in
myenteric ganglia by w50% compared with the buffer
control (53% ± 4% and 52% ± 3%, respectively; see
Figure 1G), which is consistent with the results determined
by HuC/D-immunoreactivity. Together, these results show
that the activation of glial P2Y1Rs is sufﬁcient to induce
enteric neuron death.In Situ Glial-Driven Neuron Death Requires
Connexin-43 Hemichannels
The activation of glial P2Y1Rs drives Ca2þ responses and
triggers mechanisms that lead to Cx43 hemichannel opening
in mice.4 Astroglial Cx43 hemichannel opening in the
context of neuroinﬂammation releases mediators that
contribute to the development of neuropathic pain and
neurodegeneration in the central nervous system (CNS).20,21
Thus, we tested whether glial-driven enteric neuron death
requires Cx43 hemichannel opening by activating glial
P2Y1Rs in the presence of a speciﬁc Cx43 hemichannel
mimetic peptide, 43Gap26 (100 mM), that inhibits Cx43
hemichannel opening.22
The neurotoxic effects of both P2Y1R agonists (ADP and
ADPbS) and P2X7R agonist (BzATP) were lost in the pres-
ence of 43Gap26. Ganglionic neuron density remained at
92% ± 2% of control when exposed to ADP, 89% ± 3% of
control when exposed to ADPBS and 108% ± 8% (see
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responsible for driving neuron death because Cx43 hemi-
channels are conﬁned to enteric glial cells within the ENS.4Glial Connexin-43 Hemichannels Are Required
for in Vivo Neuron Death During Inﬂammation
To more accurately test the role of glial Cx43 hemi-
channels in inﬂammatory neuropathy, we combined in vivoDNBS-colitis with a targeted gene deletion approach to
conditionally ablate Cx43 in GFAP-expressing glial cells after
the administration of tamoxifen4 (inducible and conditional
Cx43 knockout; Cx43i-cKO; Figure 2). In agreement with our
previous work, the density of HuC/D-immunoreactive
myenteric neurons was reduced by 24% (2057 ± 68
versus 1565 ± 139 neurons mm2) at the peak of DNBS
colitis in control mice (littermates treated with tamoxifen
but lacking cre recombinase in glia, Cre; see Figure 2A).
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channels in glia (Creþ) were resistant to the neurotoxic ef-
fects of in vivo inﬂammation (2057 ± 68 neurons mm2 in
Cre/saline controls versus 1850 ± 117 neurons mm2 in
Creþ/DNBS; see Figure 2A). This effect is not likely due to
an alteration in the inﬂammation driven by DNBS because
Cx43i-cKO (Creþ) mice exhibited the same pattern of weight
loss and macroscopic damage scores as littermate controls
(see Figure 2B and C). Further, the ablation of Cx43 in glia
did not affect normal neuron packing density in healthy
animals (2057 ± 68 neurons mm2 in Cre/saline animals
versus 2149 ± 101 neurons mm2 in Creþ/saline; see
Figure 2A). Collectively, these data show that the expression
of glial Cx43 hemichannels is a requirement for inﬂamma-
tory neuropathy in the ENS.
Stimulation of Enteric Glial P2Y1 Receptors
Elicits Connexin-43-Dependent Adenosine
Triphosphate Release
One possible mechanistic explanation for glial-driven
neuron death is that glial Cx43 hemichannel opening mod-
ulates P2X7R activation threshold by augmenting levels of
extracellular ATP. In support of this concept, astroglial Cx43
hemichannels are highly permeable to ATP23,24 and neuro-
toxic activation of P2X7Rs requires a conformational change
that only high concentrations of ATP are capable of inducing
by occupying all four ATP binding sites.25 We tested if
purinergic activation of enteric glia drives Cx43-dependent
ATP release by stimulating glial P2Y1Rs while monitoring
extracellular ATP release with ATP-sensitive microelec-
trodes.15 In these experiments, we either directly stimulated
glial P2Y1Rs with the nonhydrolyzable agonist ADPbS or
indirectly generated endogenous ADP by activating
neuronal P2X7R-dependent ATP release with the agonist
BzATP.
We found that stimulating glial P2Y1Rs with ADPbS
elicits robust ATP release from enteric glia (see Figure 3AFigure 1. (See previous page). Activation of enteric glial P
connexin-43 (Cx43)-dependent mechanism. (A) Schematic d
elicits Ca2þ responses in enteric glia. (B) Representative traces
human glia respond to the P2Y1R agonist adenosine diphosphat
(ATP) stimulated by the P2X7R agonist 20(30)-O-(4-benzoylbenzo
Gray traces show responses of individual glial cells within a gan
is overlaid in green. Traces are representative of recordings from
situ Ca2þ imaging of the mouse myenteric plexus demonstrates
glia. (C) Representative images of Fluo-4 ﬂuorescence in a mye
peak stimulation (at time ¼ 60 seconds) with the nonhydrolyzab
salt (ADPbS). Arrows point to representative enteric glia. (D)
(magenta dashed line) within a myenteric ganglion from the mou
responses in over 5 myenteric ganglia. (E) Representative mou
(magenta). Enteric glia are labeled with the glial cell marker gli
highlight areas of colocalization (scale bar: 30 mM). The boxed
bottom right panel to highlight a glial cell with dense P2Y1R exp
neurons in myenteric ganglia after in situ activation of P2Y1Rs
P2X7Rs with BzATP in the presence or absence of the Cx43
analysis of variance). (G) Mean packing density of live enteric n
buffer control after in situ neuroinﬂammation with BzATP or AD
images show viable cells, labeled with ﬂuorescent calcein-AM (
treated tissues. Dead (nonﬂuorescent) neurons are denoted byand B). P2Y1R-driven glial ATP release was completely
dependent upon Cx43 because ATP release was absent in
the presence of the Cx43 mimetic peptide 43Gap26 and in
tissue from Cx43i-cKO (Creþ) mice (see Figure 3A and B).
Likewise, stimulation of P2X7R-dependent neuron-glia
communication generated high levels of extracellular ATP
(see Figure 3C and D). Interestingly, panx1-dependent ATP
release from enteric neurons accounted for only approxi-
mately one-third of total ATP release while Cx43-dependent
release from glia accounted for the majority of ATP release.
These results indicate that enteric glia have the potential to
release large quantities of ATP through Cx43 hemichannels
after stimulation of P2Y1Rs.
Oxidative Stress Coincides With Neuron Death
During in Vivo Inﬂammation and Is Required for
P2X7 Receptor-Driven Neuron Death in Situ
Next, we asked whether the neurotoxic opening of glial
Cx43 channels requires potentiation of channel function by
other factors associated with inﬂammation. We initially
focused on oxidative stressors because Cx43 hemichannel
opening is potentiated by oxidative stress26 and oxidative
stress is considered a key mechanism in the pathogenesis of
gut inﬂammation.1,27,28 In support, we observed high levels
of oxidative stress in myenteric ganglia during DNBS-colitis
(see Figure 4A and C). Measures of oxidative stress included
neuronal thiol oxidation ratios (ratio of oxidized/reduced
neuronal glutathione) (see Figure 4A) and ganglionic con-
centrations of superoxide measured by ﬂuorescence of the
superoxide-speciﬁc ﬂuorescent indicator DHE (see
Figure 4C).
We conﬁrmed that our measures truly reﬂected oxida-
tive stress by administration of the antioxidant N-acetyl
cysteine (NAC, 5 g/L) in vivo before and during the induc-
tion of DNBS-colitis (see Figure 4A). Treatment with NAC
prevented increased oxidative stress during DNBS-colitis
(see Figure 4A) without altering the acute inﬂammatory2Y1 receptors (P2Y1Rs) drives neuron death through a
epicting how activation of neuronal P2X7 receptors (P2X7Rs)
of in situ Ca2þ imaging of human myenteric glia. As in mice,
e (ADP) and to the neuronal release of adenosine triphosphate
yl)adenosine 50-triphosphate triethylammonium salt (BzATP).
glion and the averaged response of all glia within the ganglion
at least 4 myenteric ganglia from the human jejunum. (C, D) In
that P2Y1R agonists primarily elicit Ca2þ responses in enteric
nteric ganglion from the mouse colon at rest (baseline) and at
le P2Y1R agonist adenosine 50-[b-thio]diphosphate trilithium
Averaged Ca2þ responses of glia (green line) and neurons
se colon in response to ADPbS. Traces are representative of
se myenteric ganglion showing immunoreactivity for P2Y1Rs
al ﬁbrillary acidic protein (GFAP; green) and the arrowheads
region in the overlay image at top right is expanded in the
ression. (F) Mean packing density of HuC/D-immunoreactive
with the agonists ADP, ADPbS and MRS2365 or activation of
inhibitor 43Gap26 (n ¼ 3–5 animals; **P  .01, ***P  .005,
eurons in myenteric ganglia expressed as the percentage of
P as quantiﬁed by calcein-AM ﬂuorescence. Representative
green), in mouse myenteric ganglia from control and BzATP-
asterisks (scale bar: 30 mM; n ¼ 3–4 animals).
Figure 2. Genetic ablation of glial Cx43 limits neuropathy
without modifying overt inﬂammation. (A) Mean packing
density of myenteric neurons after DNBS-colitis in transgenic
mice with an inducible ablation of Cx43 in glial cells (Cx43i-
cKO, Creþ) and their littermate controls (Cre). Weight loss
pattern and macroscopic damage for experimental groups
shown in B and C, respectively (n ¼ 5–7 animals; *P  .05,
analysis of variance).
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score with NAC treatment (see Figure 4B). Importantly, we
investigated the mechanistic signiﬁcance of oxidative stressand found that treatment with NAC prevented P2X7R-driven
neuron death in situ (see Figure 4D and E). Because our re-
sults show that glial pathways mediate P2X7R-driven neuron
death, they indicate that oxidative stress contributes to the
activation of neurotoxic glial mechanisms.Enteric Glia Contribute to Oxidative Stress
via Local Nitric Oxide Production
During Inﬂammation
Glial cells can directly contribute to the local generation
of oxidative stressors by up-regulating the activity of
iNOS,29,30 an enzyme that produces large amounts of NO
during inﬂammation.31 We assessed the glial contribution to
local NO levels within enteric ganglia from healthy and
inﬂamed animals by measuring cellular NO concentrations in
both neurons and glial cells with the NO-sensitive ﬂuorescent
dye DAF-FM (see Figure 5A). DAF-FM ﬂuorescence reliably
reﬂected intracellular NO concentrations because treatment
with the NO donor PAPA NONOate elevated ﬂuorescence and
treatment with the pan-NOS inhibitor L-NAME decreased
ﬂuorescence (see Figure 5A). NO was equally distributed
between neurons and glia in non-inﬂamed animals and this
distribution was not altered up to 6 hours after DNBS colitis
(see Figure 5B and C). However, we observed an elevation of
glial NO content during the peak of the inﬂammatory
response 48 hours after initiation of DNBS colitis (see
Figure 5B and C). Further, increases in immunoreactivity for
nitrated proteins, another measure of NO concentration,
correlated with changes in glial NO content after DNBS colitis
treatment (see Figure 5D). Nitrated protein immunoreac-
tivity primarily colocalized with GFAP immunoreactivity
within myenteric ganglia (see Figure 5E), suggesting that
glial cells are the main sites of nitration and other NO-
mediated modiﬁcations in the myenteric plexus during
inﬂammation. Importantly, the kinetics of glial NO produc-
tion and protein nitration coincide with the appearance of
neuron death during colitis in mice9 and guinea pigs.32Nitric Oxide Potentiates Glial Adenosine
Triphosphate Release and Promotes
Enteric Neuron Death Through a
Connexin-43-Dependent Mechanism
Given that nitrosylation of Cx43 hemichannels is asso-
ciated with increased Cx43 channel opening in astrocytes,26
we hypothesized that NO would potentiate the Cx43-
dependent release of ATP driven by glial P2Y1R activation.
In support, we found that the Cx43-dependent release of
ATP from glia stimulated by the P2Y1R agonist ADPbS was
potentiated in the presence of the NO donor PAPA NONOate
(see Figure 6A). This suggests that NO production during
intestinal inﬂammation can contribute to the activation of
the neurotoxic Cx43 pathway in enteric glia.
In situ, we observed an equal extent of neuron death in
whole-mounts of myenteric plexus incubated with the NO
donor PAPA NONOate as in preparations exposed to the
neuronal P2X7R agonist BzATP (24% ± 5% versus 21% ±
4%; see Figure 6C), further supporting a pathogenic role for
Figure 3. Stimulation of enteric glial P2Y1 receptors (P2Y1Rs) elicits connexin-43 (Cx43)-dependent adenosine
triphosphate (ATP) release. (A, C) Representative traces and (B, D) quantiﬁed measurements of ATP release from the mouse
myenteric plexus obtained with ATP-selective electrodes. Glial P2Y1Rs were directly stimulated with the P2Y1R agonist,
adenosine 50-[b-thio]diphosphate trilithium salt (ADPbS, A, B: 100 mM), or by eliciting neuron-to-glia communication with the
neuronal P2X7 receptor (P2X7R) agonist 20(30)-O-(4-benzoylbenzoyl)adenosine 50-triphosphate triethylammonium salt (BzATP,
C, D: 300 mM), in the presence or absence of the Cx43 mimetic peptide 43Gap26 (100 mM), the pannexin-1 mimetic peptide
10Panx (100 mM), or in tissue from Cx43i-cKO mice after the selective ablation of glial Cx43 (Creþ knockout or Cre littermate
controls). n ¼ 3 animals.
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toxic effects of PAPA NONOate and BzATP were not additive.
This ﬁnding suggests that NO and P2X7R agonists drive
neuron death through a common mechanism. Indeed, BzATP
and PAPA NONOate–driven neuron deaths were both
entirely dependent upon Cx43 hemichannel opening
because the neurotoxic effects of these compounds were
abolished in the presence of 43Gap26. Likewise, neurons
were protected against BzATP-induced death in tissue from
iNOS null (iNOS/) mice and by blocking NO production
from iNOS with the inhibitor 1400W (see Figure 6C).
Collectively, these data show that the production of NO by
iNOS during inﬂammation is essential for the activation of
neurotoxic pathways mediated through glial Cx43 hemi-
channels and strongly suggest that NO contributes to neu-
ropathy by potentiating glial ATP release via Cx43
hemichannels.Mechanisms of Neuron Death Downstream of
Glial P2Y1 Receptor Activation Involve Glial
Inducible Nitric Oxide Synthase and Neuronal
P2X7 Receptors
To determine the sequence of signaling events down-
stream of glial P2Y1R activation that lead to neuron death,we activated glial P2Y1Rs in situ with the speciﬁc agonist
ADP (100 mM) in the presence of drugs to inhibit either
iNOS or P2X7Rs. The inhibition of glial iNOS with 1400W33
completely abolished the neurotoxic effect of glial P2Y1R
activation (118 ± 13% versus 72 ± 7%; see Figure 6B).
Likewise, the inhibition of neuronal P2X7Rs with A-
74000334 protected against neuron death driven by glial
P2Y1R activation (90% ± 5%, versus 72% ± 7%; see
Figure 6B). Taken together, these results suggest a cyclical
signaling mechanism where neuronal P2X7R-pan-
x1–mediated ATP release activates glial P2Y1Rs and intra-
cellular signaling mechanisms that lead to glial NO
production and the potentiation of ATP release from glial
Cx43 hemichannels that causes neuron death through ac-
tions on neuronal P2X7Rs.Nitric Oxide Positively Modulates Glial
Connexin-43 Hemichannels and Negatively
Modulates Neuronal Pannexin-1 Hemichannels
NO could directly modulate a number of receptors and
channels involved in the P2X7R-panx1 neuron death
pathway, including glial Cx43 hemichannels and/or neuronal
panx1 hemichannels and P2X7Rs.35 To determine whether
the neurotoxic effect of NO we observed is due to the
Figure 4. Oxidative stress coincides with neuron death during in vivo inﬂammation and is required for P2X7 receptor
(P2X7R)-driven neuron death in situ. (A) Thiol oxidation measurements (ratio of ﬂuorescently labeled oxidized/reduced
glutathione) in myenteric neurons from healthy (saline) or inﬂamed (dinitrobenzene sulfonic acid [DNBS] colitis) animals
drinking normal water (H2O) or water containing the antioxidant N-acetyl cysteine (NAC, 5 g/L) (n ¼ 5 animals; ****P < .001,
analysis of variance [ANOVA]). (B) Macroscopic damage score for animals treated in A. (C) Ganglionic ﬂuorescence of the
superoxide indicator dihydroethidium (DHE, 2 mM) in the myenteric plexus of healthy (saline) or inﬂamed (DNBS-colitis) mice
(n ¼ 5–6 animals; *P < .05, unpaired t test). (D) Representative myenteric ganglia from in situ preparations treated with 20(30)-O-
(4-benzoylbenzoyl)adenosine 50-triphosphate triethylammonium salt (BzATP) in the presence or absence of the antioxidant
NAC. Neurons are labeled with the neuronal marker HuC/D, with dead neurons denoted by asterisks (scale bar: 30 mM). (E)
Mean packing density of HuC/D-immunoreactive neurons in myenteric ganglia after in situ activation of P2X7Rs with BzATP
(300 mM) in the presence of NAC (n ¼ 4 animals; *P < .05, ANOVA).
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signaling mechanisms, we measured glial activity induced
indirectly by the activation of neuronal P2X7R-panx1 or
directly via the activation of glial P2Y1Rs in the presence of
the NO donor PAPA NONOate (100 mM). We previously
demonstrated that enteric glia can be used as endogenous
“sniffer cells” to measure the activity of the neuronal
P2X7R-panx1 pathway9 and that glial network activity in
response to the P2Y1R agonist ADP reﬂects glial Cx43 ac-
tivity.4 Our results show that glial Ca2þ responses down-
stream of neuronal P2X7R-panx1 activation are
signiﬁcantly blunted in the presence of PAPA NONOate
(72% decrease in peak DF/F versus control; see Figure 7A
and B). Glial Ca2þ responses downstream of neuronal
P2X7R activation are entirely dependent on the neuronal
release of ATP through panx19 and blunted glial responses
suggest that NO negatively regulates P2X7R-panx1-
dependent neuron-to-glia communication. This result is in
agreement with other studies showing that NO inhibits
panx1 channel activity.35,36
An alternate explanation for this result is that NO
decreased the ability of glia to respond to neuronalactivation. We tested this possibility by directly activating
glial cells with ADP. Instead of decreasing glial responsive-
ness, we found that NO signiﬁcantly potentiated glial Ca2þ
responses to ADP (35% increase in peak DF/F versus con-
trol; see Figure 7C and D). This outcome suggests that glial
Cx43 hemichannel opening is facilitated by NO because Ca2þ
responses through the enteric glial network are mediated by
Cx43.4 Our other data support this conclusion by showing
that NO potentiates glial Cx43-dependent ATP release (see
Figure 6A). Together, these results strongly support the
conclusion that the sensitization of glial release mecha-
nisms, rather than neuronal signaling components, is the
primary cause of neuron death.Discussion
Our observations provide the ﬁrst evidence that enteric
glial cells play an active role in the death of enteric neurons
during gut inﬂammation. Speciﬁcally, our data show that
mediators of inﬂammation, such as NO, potentiate the gating
of glial Cx43 hemichannels and subsequently, neuron death.
Based on these data, we propose a model where neuronal
Figure 5. Enteric glia contribute to oxidative stress by producing nitric oxide (NO) during inﬂammation. (A–C) In situ NO
imaging with the NO sensitive dye 4-amino-5-methylamino-20,70-diﬂuoroﬂuorescein (DAF-FM). (A) Representative traces of
mean glial NO responses after treatment with the NO donor propylamine propylamine NONOate (PAPA NONOate, solid green
line, 100 mM) or the pan-nitric oxide synthase (NOS) inhibitor Nu-nitro-L-arginine methyl ester (L-NAME, dashed black line, 100
mM). (B) Representative images of DAF-FM ﬂuorescence in myenteric ganglia from healthy (saline) or inﬂamed (dinitrobenzene
sulfonic acid [DNBS] colitis) mice. Arrows point to representative glial cells and representative neurons (or the lack thereof) are
denoted by asterisks (scale bar: 30 mM). (C) Quantiﬁcation of DAF-FM ﬂuorescence in observable myenteric neurons and glia
in the healthy (saline) or inﬂamed colon at 6 hours (left) and 48 hours (right) after the initiation of DNBS-colitis (n ¼ 5–10
animals; *P < .05, t test compared to glia-saline). (D) Percentage of nitrotyrosine immunoreactive (nT þ ve) ganglia in the
myenteric plexus of saline and DNBS-treated animals at 6 hours (left) and 48 hours (right) after the initiation of DNBS-colitis
(n ¼ 3–5 animals; *P < .05, unpaired t test). (E) Representative myenteric ganglion showing immunoreactivity for nitrated
proteins (nTYR;magenta). Enteric glia are labeled with the glial cell marker GFAP (green) and yellow arrowheads highlight areas
of colocalization (scale bar: 20 mM). The boxed region in the overlay image is shown at a higher magniﬁcation to highlight
immunoreactivity of nitrated proteins on glial processes.
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Figure 6. Nitric oxide (NO) potentiates adenosine triphosphate (ATP) release from glia and promotes neuron death in
situ through a mechanism that involves glial connexin-43 (Cx43) hemichannels. (A) ATP release from myenteric ganglia
after stimulation of glial P2Y1 receptors (P2Y1Rs) with adenosine 50-[b-thio]diphosphate trilithium salt (ADPbS, 100 mM) alone
or in the presence of the NO donor propylamine propylamine NONOate (PAPA NONOate, n ¼ 4; *P < .05, unpaired t test). (B)
Mean packing density of HuC/D-immunoreactive myenteric neurons after direct glial P2Y1R stimulation with adenosine
diphosphate (ADP) and inhibition of inducible nitric oxide synthase (iNOS, 1400W; 10 mM) or P2X7 receptors (P2X7Rs,
A740003; 10 mM). Inhibition of iNOS or P2X7Rs protects against P2Y1R-driven neuron death (*P  .01, analysis of variance
[ANOVA] as compared to ADP; n ¼ 3–4 animals). (C) Mean packing density of myenteric neurons after application of BzATP or
NO-modifying drugs in wild-type (bottom bars) or iNOS-knockout mice (iNOS/, top two green bars). Inhibition (1400W; 10
mM) or ablation (iNOS/) of iNOS protects against P2X7R-driven neuron death. The NO donor PAPA NONOate (100 mM)
drives neuron death to an equal extent as BzATP but the combination is not additive. Like BzATP, PAPA NONOate–driven
neuron death requires iNOS (blocked by 1400W and in iNOS/ mice) and Cx43 hemichannel opening (blocked by 43Gap26).
*P  .05, **P  .01, ***P  .001, ****P  .0001, ANOVA as compared to BzATP; n ¼ 3–11 animals.
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or neuron stress drives glial activation leading to pathogenic
Cx43-dependent ATP release by glial cells and enteric
neuron death by activation of neuronal P2X7Rs (Figure 8).
Enteric glial cells are generally thought to support the
function and survival of enteric neurons, and models of glial
ablation support this conclusion as glial ablation produces a
rapid loss of enteric neurons.5,6 Thus, a loss of the sup-
portive roles of glial cells is postulated as a potentialmechanism for the development of ENS dysfunction in in-
ﬂammatory bowel disease.2,5 In contrast, newer data show
that the chronic activation of astroglia in the context of
neuroinﬂammation leads to the release of neurotoxic me-
diators from glial cells.7 Our results support a similar sce-
nario in the ENS during inﬂammation where a gain, rather
than a loss, of glial cell function leads to the death of enteric
neurons. These ﬁndings highlight the dichotomous roles of
enteric glial cells during health and disease and suggest that
Figure 7. Nitric oxide (NO) positively modulates glial connexin-43 (Cx43) hemichannels and negatively modulates
neuronal pannexin-1 (panx1) hemichannels. (A, B) Representative Ca2þ imaging traces (A) and averaged peak DF/F re-
sponses (B) show that NO (NO donor propylamine propylamine NONOate [PAPA NONOate]) blunts glial Ca2þ responses
downstream of neuronal P2X7 receptor (P2X7R)-panx1 stimulation with 20(30)-O-(4-benzoylbenzoyl)adenosine 50-triphosphate
triethylammonium salt (BzATP, 300 mM). (C, D) Representative Ca2þ imaging traces (C) and averaged peak DF/F responses (D)
of glial Ca2þ responses during direct glial P2Y1 receptor (P2Y1R) activation with adenosine diphosphate (ADP, 100 mM) in the
presence or absence of the NO donor PAPA NONOate. Note that NO potentiates glial network responses driven by the direct
agonist ADP. *P < .05, ****P < .001, t test compared with control; n ¼ 51–139 individual cells in 3–7 ganglia.
88 Brown et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 1either a loss of protective glial function or a gain of patho-
logic glial functions can drive ENS dysfunction but pre-
sumably through very different mechanisms.
Physiologically, enteric glial cells possess neuro-
protective properties and are integral in maintaining enteric
neuron populations. Enteric glia secrete neuroprotective
compounds such as reduced glutathione and the prosta-
glandin derivative 15-deoxy-PGJ2.3,37 Further, intra-
ganglionic enteric glia express a number of receptors and
enzymes that can respond to and degrade neuroactive
compounds, thus preventing aberrant neuronal activa-
tion.38,39 Finally, glial cells can directly participate in neuron
signaling by responding to and releasing neurotransmitters
as previously shown for Cx43 hemichannels in hippocampal
astrocytes in the CNS.40 In support of a functional role for
Cx43 hemichannels in the enteric nervous system, we
observed that ablation of Cx43 in enteric glial cells blunts
glial network activity and disrupts neuronal regulations of
gastrointestinal transit under physiologic conditions.4
Here, we ﬁnd that glial Cx43 hemichannel opening is
required for neuron death during inﬂammation and that the
selective ablation of glial Cx43 is neuroprotective in gut
pathology. We postulate that these observations reﬂect the
necessity for Cx43 hemichannels in both physiologic and
pathophysiologic functions of enteric glia, where thepathologic potential of glial Cx43 is evident when potenti-
ated by inﬂammatory mediators such as NO. Indeed, NO
potentiated Cx43-mediated ATP release from enteric glia,
driving neuron death. Although inhibition of Cx43 was
neuroprotective, the therapeutic potential of Cx43 inhibition
may be limited given the essential role of glial Cx43 in
normal gut function. However, selective inhibition of
pathologic channel opening by NO has the potential to
disrupt pathology without affecting physiologic functions.
Thus, drugs such as GW274150 [(2S)-2-amino-4-[2-(1-
aminoethylideneamino)ethylsulfanyl]butanoic acid] that
display excellent iNOS selectivity and little toxicity41 may
represent important new therapeutics in the treatment of
functional gastrointestinal disorders.
Cx43 hemichannels are subject to post-translational
modiﬁcations, including S-nitrosylation26 by increased
oxidant concentrations. Here, we show that an increase in
tryosine nitration, another NO-mediated post-translational
modiﬁcation, correlates with increased glial NO after in vivo
inﬂammation. Nitrotyrosine immunoreactivity is primarily
localized to enteric glial cells, suggesting that glial proteins
are susceptible to NO-mediated posttranslation modiﬁca-
tions. This supports our hypothesis that glial Cx43 is a
candidate of post-translational nitrosylation as a result of
increased NO production during in vivo inﬂammation. We
Figure 8. Proposed model of the mechanisms involved in
glial cell-driven enteric neuron death during acute
inﬂammation. The activation of neuronal P2X7 receptors
(P2X7Rs) leads to adenosine triphosphate (ATP) release
through pannexin-1 (panx1) channels that recruits activity in
the surrounding glia by activating glial P2Y1 receptors
(P2Y1Rs). Intracellular signaling pathways downstream of
P2Y1R activation drive glial inducible nitric oxide synthase
(iNOS) production and glial NO potentiates connexin-43
(Cx43) hemichannel-dependent ATP release. Glial NO may
also feed back on neurons to block panx1 channel activity.
Large quantities of ATP are released through glial Cx43 and
act on neuronal P2X7Rs to drive neuron death.
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using a ﬂuorescent NO marker during the initiation (6
hours) and peak (48 hours) of inﬂammation. Although we
did not observe a signiﬁcant increase in glial NO content at 6
hours after initiating inﬂammation, this could be due to the
high variability between the inﬂammatory stages of indi-
vidual ganglia at this early stage. However, our nitration
data show a similar timeline of nitration in glia, so it is likely
that glial NO production occurs in response to active
inﬂammation and is not necessarily responsible for the
initiation of inﬂammation.
One alternate interpretation of our ﬁndings is that NO
production by glia and oxidative stress in neurons directly
affects the P2X7Rs and panx1 hemichannels on enteric
neurons; leading to neuron death independent of glial
mechanisms.9 Indeed, NO modulates the activity of hemi-
channels including those composed of panx135,42,43 and
Cx43.26,44 However, we do not believe that our data support
this interpretation because of several reasons. Firstly, we
show that NO signiﬁcantly blunts glial activity initiated by
the neuronal release of ATP through P2X7R-panx1. In
contrast, NO potentiated Cx43-dependent intercellular
communication between enteric glia in response to direct
P2Y1R stimulation. Likewise, the neurotoxic effect of the NO
donor was completely abolished by the Cx43 mimetic pep-
tide or the genetic ablation of glial iNOS. Further, our
data show that glial cell release of ATP through Cx43 is
the primary contributor to extracellular ATP levels afterstimulation of either neuronal P2X7Rs or glial P2Y1Rs while
neuronal panx1 opening contributes only minor amounts of
ATP. Finally, the selective ablation of glial Cx43 alone was
able to protect enteric neurons during inﬂammation in vivo.
We interpret these ﬁndings as indicating that the potentia-
tion of neurotoxic mechanisms is primarily occurring in glial
cells although we recognize that a combination of effects on
neuronal and glial pathways could be required for neuron
death.
Our in vivo model of Cx43 ablation uses cre/lox tech-
nology and requires expression of cre recombinase, driven
by the GFAP promoter, in response to tamoxifen adminis-
tration. Although enteric glial cells are a heterogeneous
population, the majority of glia in the myenteric plexus are
GFAP positive,45 making this a suitable promoter for our
study. Importantly, our model is dependent upon tran-
scription of cre from the GFAP promoter. Thus, variability in
GFAP protein expression with inﬂammation and time would
not likely have a major effect on cre activity and Cx43
excision.45 In our experimental paradigm, inﬂammation was
induced after the ablation of Cx43 was induced. However,
enteric glia are subject to gliogenesis in response to injury
and inﬂammation.46 Any newly generated glia after
inﬂammation would not have been exposed to tamoxifen
and would express functional Cx43 hemichannels. However,
the timeline for gliogenesis46 is substantially longer than
that of our current inﬂammatory model,32 so we do not
believe that glial turnover was a major confounding factor in
these experiments.
GFAP is also expressed by astrocytes in the CNS47,48 and
tamoxifen treatment in our mouse model induces the abla-
tion of Cx43 hemichannels in enteric glia and CNS astro-
cytes. Disruption of the astrocytic Cx43 gap junction and
hemichannel function results in CNS dysfunction and this
may have exerted confounding effects in our disease model.
However, we do not observe unusual weight loss or gut
inﬂammation in these animals in the absence of inﬂamma-
tory stimuli and we observed comparable weight loss and
inﬂammation to wild-type animals during inﬂammation (see
Figure 2). Thus, dysfunction in the brain-gut axis does not
seem to be a signiﬁcant contributor to disease outcome in
our in vivo model.
Purinergic activation of enteric glial cells is a central
component of our proposed signaling mechanism (Figure 8).
We show that glial purinergic responses are mediated
through P2Y1Rs that are primarily localized to enteric glial
cells in the mouse myenteric plexus. This supports previous
work demonstrating glial P2Y1R expression and activity in
cultured glial cells19 and in whole-mount preparations in
the mouse and guinea pig.9,49,50 Previous work suggests
P2Y1R expression on enteric neurons.18,51 However, we
demonstrate that activation with the P2Y1R agonist ADP
elicits Ca2þ responses in glial cells, a phenomenon observed
in the CNS notwithstanding P2Y1R expression on both
neurons and astrocytes.52 Given the present data, it is
tempting to speculate that the P2Y1R-mediated slow excit-
atory postsynaptic potentials recorded in enteric neurons51
are actually downstream of glial activation and this will be
an interesting hypothesis to test in future experiments.
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for enteric glia in the pathogenesis of enteric neuropathies.
Enteric neuropathy is increasingly recognized as a key
pathologic ﬁnding in functional gastrointestinal disorders,
including irritable bowel syndrome53 and slow transit
constipation.54 Inﬂammation is thought to produce
persistent gut dysfunction through effects on the ENS,
including enteric neuron death and the functional remod-
eling of enteric circuitry. Indeed, our prior results show
that an acute inﬂammatory event triggers enteric neuron
death and leads to gut motor dysfunction that persists
despite resolution of active inﬂammation.9 Our current
observations suggest that the activation of enteric glial
cells is necessary for at least a portion of these permanent
effects on the ENS. Thus, new therapies that modulate the
pathophysiologic functions of enteric glial cells could lead
to the development of more effective treatments for func-
tional bowel disorders.References
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